This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sinclair, P. B. Articles by Foroni, L. Search for Related Content PubMed PubMed Citation Articles by Sinclair, P. B. Articles by Foroni, L.

A Fluorescence in Situ Hybridization Map of 6q Deletions in Acute Lymphocytic Leukemia

Identification and Analysis of a Candidate Tumor Suppressor Gene

Haematology Department, Royal Free and University College School of Medicine, London, United Kingdom

With the objective of identifying candidate tumor suppressor genes, we used fluorescence in situ hybridization to map leukemia-related deletions of the long arm of chromosome 6 (6q). Twenty of 24 deletions overlapped to define a 4.8-Mb region of minimal deletion between markers D6S1510 and D6S1692 within chromosome 6 band q16. Using reverse transcription-PCR, we found evidence of expression in hematopoietic cells for 3 of 15 genes in the region (GRIK2, C6orf111, and CCNC). Comparison between our own and published deletion data singled out GRIK2 as the gene most frequently affected by deletions of 6q in acute lymphocytic leukemia (ALL). Sequence analysis of GRIK2 in 14 ALL cases carrying heterozygous 6q deletions revealed a constitutional and paternally inherited C to G substitution in exon 6 encoding for an amino acid change in one patient. The substitution was absent among 232 normal alleles tested, leaving open the possibility that heterozygous carriers of such mutations may be susceptible to ALL. Although low in all normal hematopoietic tissues, quantitative reverse transcription-PCR showed higher baseline GRIK2 expression in thymus and T cells than other lineages. Among T-cell ALL patients, 6q deletion was associated with a statistically significant reduction in GRIK2 expression (P = 0.0001). By contrast, elevated GRIK2 expression was measured in the myelomonocytic line THP-1 and in one patient with common ALL. Finally, we detected significant levels of GRIK2 expression in prostate, kidney, trachea, and lung, raising the possibility that this gene may be protective against multiple tumor types.

This article has been cited by other articles:

				E. Forestier, S. Izraeli, B. Beverloo, O. Haas, A. Pession, K. Michalova, B. Stark, C. J. Harrison, A. Teigler-Schlegel, and B. Johansson Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study Blood, February 1, 2008; 111(3): 1575 - 1583. [Abstract] [Full Text] [PDF]

				M. S. Kim, K. Yamashita, Y. K. Chae, Y. Tokumaru, X. Chang, M. Zahurak, M. Osada, H. L. Park, A. Chuang, J. A. Califano, et al. A Promoter Methylation Pattern in the N-Methyl-D-Aspartate Receptor 2B Gene Predicts Poor Prognosis in Esophageal Squamous Cell Carcinoma Clin. Cancer Res., November 15, 2007; 13(22): 6658 - 6665. [Abstract] [Full Text] [PDF]

				M. S. Kim, K. Yamashita, J. H. Baek, H. L. Park, A. L. Carvalho, M. Osada, M. O. Hoque, S. Upadhyay, M. Mori, C. Moon, et al. N-methyl-D-aspartate receptor type 2B is epigenetically inactivated and exhibits tumor-suppressive activity in human esophageal cancer. Cancer Res., April 1, 2006; 66(7): 3409 - 3418. [Abstract] [Full Text] [PDF]

				A. Ghosh, X. Wang, E. Klein, and W. D.W. Heston Novel Role of Prostate-Specific Membrane Antigen in Suppressing Prostate Cancer Invasiveness Cancer Res., February 1, 2005; 65(3): 727 - 731. [Abstract] [Full Text] [PDF]

				P. B. Sinclair, W. Mitchell, J. Kaeda, and L. Foroni Cyclin-C: Analysis of a Candidate Tumour Suppressor Genes on 6q15-q21 in Malignant Lymphoid Cell Lines and Lymphoid Acute Leukemias. Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 4332 - 4332. [Abstract]